Drug research

XPro1595

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as DN-TNF; INB03/XPro™; XENP1595

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387	INMB	Phase 2	Terminated	2024-06-05Actual
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976	INMB	Phase 2	Completed	2025-05-12Actual

INMBTerminatedPrimary completion: 2024-06-05 · Actual

Trial details

INMBCompletedPrimary completion: 2025-05-12 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.